184 related articles for article (PubMed ID: 29356399)
1. SALL4 - KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer.
Matsumoto Y; Itou J; Sato F; Toi M
Cancer Med; 2018 Feb; 7(2):454-462. PubMed ID: 29356399
[TBL] [Abstract][Full Text] [Related]
2. TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44.
Chen Q; Gu M; Cai ZK; Zhao H; Sun SC; Liu C; Zhan M; Chen YB; Wang Z
Cell Mol Life Sci; 2021 Feb; 78(3):949-962. PubMed ID: 32440711
[TBL] [Abstract][Full Text] [Related]
3. A CD44v
Hu J; Li G; Zhang P; Zhuang X; Hu G
Cell Death Dis; 2017 Mar; 8(3):e2679. PubMed ID: 28300837
[TBL] [Abstract][Full Text] [Related]
4. TDP43 promotes stemness of breast cancer stem cells through CD44 variant splicing isoforms.
Guo L; Ke H; Zhang H; Zou L; Yang Q; Lu X; Zhao L; Jiao B
Cell Death Dis; 2022 May; 13(5):428. PubMed ID: 35504883
[TBL] [Abstract][Full Text] [Related]
5. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell.
Yae T; Tsuchihashi K; Ishimoto T; Motohara T; Yoshikawa M; Yoshida GJ; Wada T; Masuko T; Mogushi K; Tanaka H; Osawa T; Kanki Y; Minami T; Aburatani H; Ohmura M; Kubo A; Suematsu M; Takahashi K; Saya H; Nagano O
Nat Commun; 2012 Jun; 3():883. PubMed ID: 22673910
[TBL] [Abstract][Full Text] [Related]
6. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.
Olsson E; Honeth G; Bendahl PO; Saal LH; Gruvberger-Saal S; Ringnér M; Vallon-Christersson J; Jönsson G; Holm K; Lövgren K; Fernö M; Grabau D; Borg A; Hegardt C
BMC Cancer; 2011 Sep; 11():418. PubMed ID: 21957977
[TBL] [Abstract][Full Text] [Related]
7. CD44 splice isoform switching determines breast cancer stem cell state.
Zhang H; Brown RL; Wei Y; Zhao P; Liu S; Liu X; Deng Y; Hu X; Zhang J; Gao XD; Kang Y; Mercurio AM; Goel HL; Cheng C
Genes Dev; 2019 Feb; 33(3-4):166-179. PubMed ID: 30692202
[TBL] [Abstract][Full Text] [Related]
8. CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism.
Gao R; Li D; Xun J; Zhou W; Li J; Wang J; Liu C; Li X; Shen W; Qiao H; Stupack DG; Luo N
Theranostics; 2018; 8(22):6248-6262. PubMed ID: 30613295
[TBL] [Abstract][Full Text] [Related]
9. Sal-like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer.
Itou J; Matsumoto Y; Yoshikawa K; Toi M
FEBS Lett; 2013 Sep; 587(18):3115-21. PubMed ID: 23954296
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal splice isoform of CD44 (CD44s) promotes EMT/invasion and imparts stem-like properties to ovarian cancer cells.
Bhattacharya R; Mitra T; Ray Chaudhuri S; Roy SS
J Cell Biochem; 2018 Apr; 119(4):3373-3383. PubMed ID: 29130517
[TBL] [Abstract][Full Text] [Related]
11. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
12. P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer.
Vieira AF; Ricardo S; Ablett MP; Dionísio MR; Mendes N; Albergaria A; Farnie G; Gerhard R; Cameselle-Teijeiro JF; Seruca R; Schmitt F; Clarke RB; Paredes J
Stem Cells; 2012 May; 30(5):854-64. PubMed ID: 22389315
[TBL] [Abstract][Full Text] [Related]
13. The p53-induced RNA-binding protein ZMAT3 is a splicing regulator that inhibits the splicing of oncogenic CD44 variants in colorectal carcinoma.
Muys BR; Anastasakis DG; Claypool D; Pongor L; Li XL; Grammatikakis I; Liu M; Wang X; Prasanth KV; Aladjem MI; Lal A; Hafner M
Genes Dev; 2021 Jan; 35(1-2):102-116. PubMed ID: 33334821
[TBL] [Abstract][Full Text] [Related]
14. Cell fate determination factor Dachshund reprograms breast cancer stem cell function.
Wu K; Jiao X; Li Z; Katiyar S; Casimiro MC; Yang W; Zhang Q; Willmarth NE; Chepelev I; Crosariol M; Wei Z; Hu J; Zhao K; Pestell RG
J Biol Chem; 2011 Jan; 286(3):2132-42. PubMed ID: 20937839
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
[TBL] [Abstract][Full Text] [Related]
16. High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: Implications for cancer stem cell resistance.
Ryoo IG; Choi BH; Ku SK; Kwak MK
Redox Biol; 2018 Jul; 17():246-258. PubMed ID: 29729523
[TBL] [Abstract][Full Text] [Related]
17. Aspartyl Aminopeptidase Suppresses Proliferation, Invasion, and Stemness of Breast Cancer Cells via Targeting CD44.
Geng N; Zhang W; Li Y; Li F
Anat Rec (Hoboken); 2019 Dec; 302(12):2178-2185. PubMed ID: 31228326
[TBL] [Abstract][Full Text] [Related]
18. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
19. KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer.
Ukai S; Sakamoto N; Taniyama D; Harada K; Honma R; Maruyama R; Naka K; Hinoi T; Takakura Y; Shimizu W; Ohdan H; Yasui W
Cancer Sci; 2021 Mar; 112(3):1196-1208. PubMed ID: 33423358
[TBL] [Abstract][Full Text] [Related]
20. CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity.
Montgomery N; Hill A; McFarlane S; Neisen J; O'Grady A; Conlon S; Jirstrom K; Kay EW; Waugh DJ
Breast Cancer Res; 2012 May; 14(3):R84. PubMed ID: 22621373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
